SPHL:NASDAQSpringview Holdings Ltd Analysis
Data as of 2026-05-02 - not real-time
$2.59
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Springview Holdings trades at $2.59, hovering just above the computed support of $2.175 but still below the 50‑day SMA of $2.70, indicating limited upside in the near term. The 20‑day SMA of $2.50 lies beneath the current price, offering a modest technical cushion, yet the overall trend is classified as bearish and the RSI sits at a neutral 49.6, suggesting no immediate momentum reversal. MACD shows a slight bullish histogram (+0.03) but both the MACD line and signal remain negative, underscoring lingering weakness. Volatility is extreme, with a 30‑day swing of roughly 99%, and beta exceeds 2.0, meaning the stock moves more than twice the market and amplifies downside risk. The company’s fundamentals are distressing: revenue has fallen 24.7%, gross margin is a meager 5.3%, and operating and profit margins are deeply negative at –14% and –23.5% respectively. Cash flow is negative, with operating cash flow of –$1.86 M and free cash flow of –$1.57 M, while debt‑to‑equity is an alarming 17.3, reflecting a heavily leveraged balance sheet. The price‑to‑book ratio of 6.75 and price‑to‑sales of 0.77 further signal that the market is pricing the stock well above its book value despite weak earnings. Liquidity is constrained, evidenced by a market cap of only $5.86 M and an average daily volume under 8 k shares, which has been decreasing. The “Extreme Greed” reading of the fear‑greed index (91.09) suggests speculative enthusiasm that may be disconnected from underlying fundamentals. Given the confluence of technical weakness, high volatility, severe financial distress, and limited liquidity, the outlook remains decidedly negative.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 7/10
Key Factors
- Price near support with bearish technical trend
- Extreme short‑term volatility and high beta
- Negative cash flow and widening losses
Medium Term
1–3 yearsCautious
Model confidence: 8/10
Key Factors
- Continued revenue decline and weak margins
- Elevated debt‑to‑equity ratio stressing balance sheet
- Low liquidity limiting ability to enter/exit positions
Long Term
> 3 yearsCautious
Model confidence: 6/10
Key Factors
- Fundamental turnaround unlikely without capital restructuring
- Sector cyclicality may prolong recovery
- Market sentiment driven by speculation rather than fundamentals
Key Metrics & Analysis
Financial Health
Revenue Growth-24.70%
Profit Margin-23.56%
ROE-46.44%
ROA-16.06%
Debt/Equity17.27
P/B Ratio6.7
Op. Cash Flow$-1861328
Free Cash Flow$-1568308
Technical Analysis
TrendBearish
RSI49.6
Support$2.17
Resistance$3.02
MA 20$2.50
MA 50$2.70
MA 200$3.71
MACDBullish
VolumeDecreasing
Fear & Greed Index91.09
Valuation
GradeOvervalued
TypeValue
Risk Assessment
Beta2.01
Volatility99.00%
Sector RiskHigh
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.